Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement

RET rearrangements are rare, and occur in 1%-2% of all non-small cell lung cancer (NSCLC) patients. Pralsetinib has a significant anti-tumor effect in patients with advanced NSCLC and a RET rearrangement. Previous studies have confirmed the efficiency of neoadjuvant target therapy for NSCLC. Herein...

Full description

Bibliographic Details
Main Authors: Ning Zhou, Tong Li, Maoli Liang, Fan Ren, Hong Ni, Wei Liu, Tao Shi, Dongbo Xu, Qiusong Chen, Haonan Yu, Zuoqing Song, Lingling Zu, Shuo Li, Song Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-02-01
Series:Frontiers in Oncology
Subjects:
RET
pralsetinib
locally advanced (stage III) non-small cell lung cancer
neoadjuvant
targeted therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.848779/full

Similar Items

Similar Items